Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other equities research analysts also recently commented on the stock. Zacks Research upgraded shares of Seres Therapeutics to a “hold” rating in a research note on Tuesday, June 23rd. HC Wainwright assumed coverage on shares of Seres Therapeutics in a research report on Tuesday, June 23rd. They set a “buy” rating and a $12.00 target price for the company. Finally, Weiss Ratings downgraded shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $17.00.

Seres Therapeutics Trading Up 1.0%

Shares of MCRB opened at $4.87 on Friday. The stock has a market cap of $48.41 million, a PE ratio of -2.00 and a beta of 0.20. Seres Therapeutics has a 1 year low of $4.59 and a 1 year high of $29.98. The stock has a 50 day simple moving average of $6.18 and a 200-day simple moving average of $8.45.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, beating the consensus estimate of ($2.18) by $2.65. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%.The business had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.18 million. On average, sell-side analysts forecast that Seres Therapeutics will post -4.36 EPS for the current fiscal year.

Institutional Trading of Seres Therapeutics

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in shares of Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,157 shares in the last quarter. Barclays PLC grew its holdings in Seres Therapeutics by 427.8% during the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 6,024 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in Seres Therapeutics during the 4th quarter worth about $190,000. Goldman Sachs Group Inc. acquired a new stake in Seres Therapeutics in the 4th quarter valued at about $213,000. Finally, Invesco Ltd. raised its stake in shares of Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 3,918 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.